EURION Virtual Stakeholder Workshop - 02 Dec 2022 | Online
The second online Stakeholder Workshop was held on 2 December 2022. The purpose of this workshop was again to present and discuss stakeholder views, needs and expectations related to EDC test method development and international strategies and guidelines. Attendees included representatives from research, regulatory authorities, industry, civil society, contract research organisations, policymakers as well as other experts working in the field of EDCs. After short highlight presentations from the eight cluster projects, talks were given by representatives from EFSA, CEFIC, CHEMTrust and ECHA. Based on these inputs, the floor was then open for feedback and recommendations from the various cluster stakeholders.
EURION Adverse Outcome Pathway (AOP) Workshop - 27 Jan 2021 | Madrid, Spain
The first AOP development workshop was organised and aligned with the EURION Annual Cluster Meeting, facilitating collaborative AOP development and entering of project data into the AOP-WIKI.
EURION Virtual Stakeholder Workshop - 11 Dec 2020 | Online
The first EURION Stakeholder Workshop was held online on 11 December 2020 and gathered representatives from research, regulatory authorities, industry, civil society and contract research organisations and policymakers as well as other experts working in the field of EDCs. The purpose of the workshop was to present and discuss stakeholder views, needs and expectations in relation to EDC test method development, international strategies and guidelines.
EURION Validation Workshop - 04 Feb 2020 | 11 Rue Watt, 75013 Paris, France
At the completion of this EURION 2020 validation training, participants will:-
- Understand the critical aspects to take into account when designing, optimising and ensuring the reliability, relevance and fitness-for-purpose of newly developed in vitro
- Get an overview of the different players involved in the process of test method development, optimisation and if applicable, the agencies involved in the validation of new methods and the pathways to regulatory acceptance.
The training addressed the critical aspects of quality for in vitro methods, as described in the OECD Good In Vitro Method Practices (GIVIMP) document, and illustrated how application of these principles improves the scientific integrity of new methods and may speed up regulatory acceptance of new proposed methods. The applicability/extrapolation of these principles to in vivo methods were also discussed.